Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore

Journal of Medicinal Chemistry

Volumn 49, Issue 18, 2006, Pages 5610-5617

  Balboni, Gianfranco ^a,b   Onnis, Valentina ^a   Congiu, Cenzo ^a   Zotti, Margherita ^b   Sasaki, Yusuke ^c   Ambo, Akihiro ^c   Bryant, Sharon D ^d   Jinsmaa, Yunden ^d   Lazarus, Lawrence H ^d   Trapella, Claudio ^b   Salvadori, Severo ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; GLYCINE; LYSINE; MU OPIATE RECEPTOR AGONIST; PEPTIDE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PEPTIDE SYNTHESIS; PHARMACOPHORE; RECEPTOR AFFINITY;

ANIMALS; DIPEPTIDES; ELECTRIC STIMULATION; GUINEA PIGS; ILEUM; LIGANDS; MALE; MICE; MUSCLE, SMOOTH; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; VAS DEFERENS;

EID: 33748545633     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060741w     Document Type: Article

References (48)

1. Abbreviations. In addition to the IUPAC-IUB Commission on Biochemical Nomenclature (J. Biol. Chem. 1985, 260, 14-42), this paper uses additional symbols and abbreviations, which are listed in Abbreviations.
2. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ Opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
3. Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow δ antagonists to manifest μ agonism or δ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
4. Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; Tomatis, R.; Lazarus, L. H.; Tancredi, T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
5. Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Lemieux, C.; Chung, N. N. Differential stereochemical requirements of μ vs δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11871-11875.
6. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni, G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging drug applications. Drug Discovery Today 1998, 3, 284-294.
7. Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. Dmt and opioid peptides: A potent alliance. Biopolymers 2003, 71, 86-102.
8. Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-Terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
9. Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides 2000, 21, 1663-1671.
10. Capasso, A.; Amodeo, P.; Balboni, G.; Guerrini, R.; Lazarus, L. H.; Temussi, P. A.; Salvadori, S. Design of μ selective opioid dipeptide antagonists. FEBS Lett. 1997, 417, 141-144.
11. Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ-opioid receptor antagonist into a potent δ-agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
12. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R′ analogues: Acquisition of potent ä antagonism. Bioorg. Med. Chem. 2003, 11, 5435-5441.
13. (a) Balboni, G.; Salvadori, S.; Dal Piaz, A.; Bortolotti, F.; Argazzi, R.; Negri, L.; Lattanzi, R.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Highly selective fluorescent analogue of the potent δ-opioid receptor antagonist Dmt-Tic. J. Med. Chem. 2004, 47, 6541-6546.
14. (b) Vázquez, M. E.; Blanco, J. B.; Salvadori, S.; Trapella, C.; Argazzi, R.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H.; Negri, L.; Giannini, E.; Lattanzi, R.; Colucci, M.; Balboni, G. 6-N,N-Dimethylamino-2,3-naphthalimide a new environment-sensitive fluorescent probe in δ-selective and μ-selective opioid peptides. J. Med. Chem. 2006, 49, 3653-3658.
15. 1-benzimidazole alkylation. J. Med. Chem. 2005, 48, 8112-8114.
16. Page', D.; Nguyen, N.; Bernard, S.; Coupai, M.; Gosselin, M.; Lepage, J.; Adam, L.; Brown, W. New scaffolds in the development of mu opioid-receptor ligands. Bioorg. Med. Chem. Lett. 2003, 13, 1585-1589.
17. Van den Eynde, L; Laus, G.; Schiller, P. W.; Kosson, P.; Chung, N. N.; Lipkowski, A. W.; Tourwé, D. A new stuctural motif for μ-opioid antagonists. J. Med. Chem. 2005, 48, 3644-3648.
18. Schiller, P. W. Opioid peptide-derived analgesics. AAPS Journal 2005, 7, E560-E565.
19. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Direct influence of the C-terminally substituted amino acids in the Dmt-Tic pharmacophore on δ-opioid receptor selectivity and antagonism. J. Med. Chem. 2004, 47, 4066-4071.
20. 2 to the potent δ antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J. Med. Chem. 2005, 48, 5608-5611.
21. Mollica, A.; Davis, P.; Ma, S.-W.; Porreca, F.; Lai, J.; Hruby, V. J. Synthesis and biological activity of the first cyclic biphalin analogues. Bioorg. Med. Chem. Lett. 2006, 16, 367-372.
22. 2[Ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J. Med. Chem. 1999, 42, 3520-3526.
23. Ananthan, S.; Khare, N. K.; Saini, S. K.; Seitz, L. E.; Bartlett, J. L.; Davis, P.; Dersch, C. M.; Porreca, F.; Rothman, R. B.; Bilsky, E. J. Identification of opioid ligands possessing mixed μ agonist/δ antagonist activity among pyridomorphinans derived from naloxone, oxymorphone and hydromorphone. J. Med. Chem. 2004, 47, 1400-1412.
24. Varga, E. V.; Navratilova, E.; Stropova, D.; Jambrosic, J.; Roeske, W. R.; Yamamura, H. I. Agonist-specific regulation of the δ-opioid receptor. Life Sci. 2004, 76, 599-612.
25. Torregrossa, M. M.; Jutkiewicz, E. M.; Mosberg, H. I.; Balboni, G.; Watson, S. J.; Woods, J. H. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 2006, 1069, 172-181 and references herein.
26. Saitoh, A.; Kimura, Y.; Suzuki, T.; Kawai, K.; Nagase, H.; Kamei, J. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J. Pharmacol. Sci. 2004, 95, 374-380.
27. Aharoni, R.; Eilam, R.; Domev, H.; Labunskay, G.; Sela, M.; Arnon, R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 19045-19050.
28. Zhang, J.; Gibney, G. T.; Zhao, P.; Xia, Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am. J. Physiol. 2002, 282, C1225-C1234.
29. 5) enkephalin: linking hibernation and neuroprotection. Front. Biosci. 2004, 9, 3392-3398.
30. Vecchio, L.; Soldani, C.; Bottone, M. G.; Malatesta, M.; Martin, T. E.; Rothblum, L. I.; Pellicciari, C.; Biggiogera, M. DADLE induces a reversible hibernation-like state in HeLa cells. Histochem. Cell Biol. 2006, 125, 193-201.
31. Peart, J. N.; Gross, G. J. Exogenous activation of delta- and kappa-opioid receptors affords cardioprotection in isolated murine heart. Basic Res. Cardiol. 2004, 99, 29-37.
32. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Potent δ-opioid receptor agonists containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5556-5563.
33. Zadina, J. E.; Hackler, L.; Ge, L. J.; Kastin, A. J. A potent and selective endogenous agonist for the mu opiate receptor. Nature 1997, 386, 499-502.
34. Kramer, T. H.; Shook, J. E.; Kazmierski, W.; Ayres, E. A.; Wire, W. S.; Hruby, V. J.; Burks, T. F. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 1989, 249, 544-551.
35. Israel, Y.; Kandov, Y.; Khaimova, E.; Kest, A.; Lewis, S. R.; Pasternak, G. W.; Pan, Y. X.; Rossi, G. C.; Bodnar, R. J. NPY-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. Peptides 2005, 26, 1167-1175.
36. (a) Roberts, A. J.; McDonald, J. S.; Heyser, C. J.; Kieffer, B. L.; Matthes, H. W. D.; Koob, G. F.; Gold, L. H. μ-opioid receptor knockout mice do not self-administer alcohol. J. Pharmacol. Exp. Ther. 2000, 293, 1002-1008.
37. (b) Krystal, J. H.; Cramer, J. A.; Krol, W. F.; Kirk, G. F.; Rosenheck, R. A. Naltrexone in the treatment of alcohol dependence. New Engl. J. Med. 2001, 345, 1734-1739.
38. (c) Hall, F. S.; Sora, I.; Uhl, G. R. Ethanol consumption and reward are decreased in μ-opiate receptor knockout mice. Psychopharmacology 2001, 154, 43-49.
39. (d) Oslin, D. W.; Berrettini, W.; Kranzler, H. R.; Pettinati, H.; Gelernter, J.; Volpicelli, J. R.; O'Brien, C. P. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28, 1546-1552.
40. (e) Oswald, L. H.; Wand, G. S. Opioids and alcoholism. Physiol. Behav. 2004, 81, 339-358.
41. Lazarus, L. H.; Salvadori, S.; Santagada, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1355.
42. Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.; Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid receptors: Molecular determinants for affinity and selectivity. Peptides 1993, 14, 21-28.
43. Lazarus, L. H.; Wilson, W. E.; de Castglione, R.; Guglietta, A. Dermorphin gene sequence peptide with high affinity and selectivity for δ-opioid receptors. J. Biol. Chem. 1989, 264, 3047-3050.
44. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
45. Sasaki, Y.; Sasaki, A.; Niizuma, H.; Goto, H.; Ambo, A. Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high μ-opioid receptor affinity and selectivity. Bioorg. Med. Chem. 2003, 11, 675-678.
46. Arunlakshana, Q.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
47. Damour, D.; Herman, F.; Labaudiniere, R.; Pantel, G.; Vuilhorgne, M.; Mignani, S. Synthesis of novel proline and γ-lactam derivatives as non-peptide mimics of somatostatin/sandostatin. Tetrahedron 1999, 55, 10135-10154.
48. Maekawa, K.; Ohtani, J. Synthese von 2-(1′-amino-1′- substituiertem alkyl)-benzimidazol aus aminosäuren und ihre biologische aktivität. Agric. Biol. Chem. 1976, 40, 791-799.